Browsing by Type "Mock Grant Proposals"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item CLINICALLY SAFE THERAPEUTIC DELIVERY USING HUMAN MESENCHYMAL STEM/STROMAL CELL-DERIVED EXOSOMAL HYBRIDS(2018-11-29) Takacs, Joseph; Candiello, Joseph; Boyd, Ann; Hirschhorn, Ricky; Biology; Biomedical ScienceAs gene therapy techniques become more aggressive with site-specific therapeutics aimed at treating diseases such as hereditary, infectious, and neoplastic diseases at the DNA level, the parallel development of standardized, clinically safe delivery methods is paramount. Completion of this study will result in a clinically safe method to deliver large therapeutic payloads in vitro, while avoiding randomly integrated sites within the genome, incomplete therapeutic effects, and presentation of other unwanted activity typically attributed to other common viral-based delivery methods. The proposed exosome-liposome hybrid will serve as a baseline for the systems’ translational potential as further modifications to the liposomal construct must be explored before clinical application.Item STUDIES OF BRCA1 PROTEIN USING CRISPR/CAS9 GENE EDITING IN HCC1937 BREAST CANCER CELLSBAITY, ALI; BEYER, RACHEL; BIOMEDICAL SCIENCEThe mutation in the BRCA1 gene in HCC1937 breast cancer cell lines produces a truncated protein that prevents interaction between BRCA1 protein and its partner called CtIP protein. The DNA repair processing needs this interaction to initiate double-strand repair. CRISPR/Cas9 system gene editing will be used to correct this mutation by deleting the insertion of cytosine at position 5382 in the wild-type BRCA1 protein. Co-immunoprecipitation (Co-IP) and western-blot assays will be used to confirm the protein interaction after correction by CRISPR/Cas9 system gene editing. Moreover, DNA repair and IR sensitivity assays will be conducted to study the BRCA1 response in these cell lines. The rate of proliferation and invasion between mutated, corrected and normal cell lines will be measured by using MTT (3-(4,5- dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide) and Transwell assays.Item USE OF HSP90 INHIBITORS TO OVERCOME TRASTUZUMAB RESISITANCE IN THE MINOR VARIANT OF HER2 P95HER2 IN BREAST CANCER(2018-11-30) Alraddadi, Mohammed; Beyer, Rachel; Department of Biology; Biomedical Science